Sai Parenterals Ltd.

556.10-14.6 (-2.56%)

17 Jul, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Sai Parenterals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M PRESS
Total Revenue	96.80	153.76	163.10	381.00
Cost of Operating Revenue	65.16	107.02	104.43	259.07
Gross Profit	31.64	46.74	58.67	121.92
Gross Margin	32.7	30.4	36.0	32.0
Total Operating Expenses	83.89	131.51	131.40	359.15
Operating Profit	12.90	22.25	31.71	21.85
Operating Margin	13.3	14.5	19.4	5.7
Financing Income/(Expense) - Net	-5.69	-10.69	-12.08	-18.44
Profit before Taxes	7.25	12.55	19.91	11.93
Income Taxes	2.88	4.14	5.48	-2.33
Profit after Tax	4.38	8.42	14.45	14.26
PAT Margin	4.5	5.5	8.9	3.7
EPS - Basic - ex Extraordinary Items	0.99	1.90	3.27	4.36
EPS - Diluted - ex Extraordinary Items	0.99	1.90	3.27	4.36
EBIT	12.90	22.25	31.71	21.85
EBITDA	18.70	31.67	39.91	38.70
EBITDA Margin	19.3	20.6	24.5	10.2

Balance Sheet

Abridged

Understanding Balance Sheet

Sai Parenterals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	PRESS
Total Current Assets	82	187	200	822
Long-Term Investments	1	1	1	2
Property Plant & Equipment - Net	45	60	44	403
Total Non-Current Assets	52	81	72	602
Total Assets	134	268	272	1,424
Total Current Liabilities	77	153	162	573
Long Term Debt	26	39	14	90
Total Non-Current Liabilities	26	39	14	356
Total Liabilities	102	192	177	929
Total Shareholders' Equity	31	75	94	491
Minority Interest	-	2	2	4
Total Equity	31	76	96	495
Total Liabilities & Equity	134	268	272	1,424

Cash Flow

Abridged

Understanding Cash Flow Statement

Sai Parenterals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M PRESS
Operating CF bef Changes in Working Cap	11.57	22.52	28.21	22.48
Working Capital - Increase/(Decrease)	-28.92	-63.08	-6.64	55.51
Net CF from Operating Activities	-17.35	-40.55	21.57	77.99
Capital Expenditures - Net	17.34	42.50	-8.27	277.20
Net CF from Investing Activities	-19.29	-46.64	0.11	-277.20
Stock - Issuance/(Retirement) - Net	2.58	39.44	0.86	253.07
Debt - LT & ST - Issuance/(Retirement) - Total	33.38	50.24	-24.83	225.53
Net Cash Flow from Financing Activities	28.79	89.68	-23.97	614.09
Free Cash Flow to Equity	-1.31	-32.81	5.00	26.32
Free Operating CF net dividend	-34.69	-84.65	21.07	-199.21
Free Operating CF	-34.69	-84.65	21.07	-199.21

Business Segment Analysis

Sai Parenterals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Sai Parenterals Ltd.

Regional Segment Analysis

Sai Parenterals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Sai Parenterals Ltd.

Historical Segment Analysis

Track how Sai Parenterals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Sai Parenterals Ltd.

Frequently Asked Questions

What is the revenue of Sai Parenterals Ltd.?

The latest trailing twelve month revenue of Sai Parenterals Ltd. is ₹ 381.00 Cr, reflecting a 1-year growth of 133.59% and a 3-year CAGR of 57.89%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sai Parenterals Ltd.?

The latest trailing twelve month net profit (PAT) of Sai Parenterals Ltd. is ₹ 14.26 Cr, with a 3-year earnings CAGR of 63.89%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sai Parenterals Ltd.?

The trailing twelve month EBITDA of Sai Parenterals Ltd. is approximately ₹ 21.85 Cr (based on an operating margin of 5.73%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sai Parenterals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sai Parenterals Ltd. is 4.36. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sai Parenterals Ltd.?

The debt-to-equity ratio of Sai Parenterals Ltd. stands at 0.68. The interest coverage ratio is 1.18x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sai Parenterals Ltd.?

The estimated book value per share of Sai Parenterals Ltd. is 111.09 (derived from a P/B ratio of 5.01 and market price of ₹ 556.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sai Parenterals Ltd.?

The trailing twelve month operating cash flow of Sai Parenterals Ltd. is ₹ 77.99 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sai Parenterals Ltd. report consolidated or standalone financials?

Sai Parenterals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.